Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04043897 · ClinicalTrials.gov registry record · Phase 2
Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis
A Phase 2 study of Microscopic Colitis, sponsored by Eugene F Yen, MD.
- Recruiting
- Registry status
- Phase 2
- Development phase
- 10
- Enrollment target
- 1
- Study location
NCT04043897 is a Phase 2 study of Microscopic Colitis that is actively recruiting participants, run by Eugene F Yen, MD. The registered enrollment target is 10 participants. The trial reports 1 study location across 1 state.
The verdict
NCT04043897, a Phase 2 study of Microscopic Colitis, is actively recruiting participants, sponsored by Eugene F Yen, MD.
- RECRUITING
- Registry status
- Phase 2
- Development phase
- 10 participants
- Enrollment target
- 1
- Study location
Study Summary
This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.
Conditions Studied
Interventions
- DRUG Rifaximin 550mg
Study Locations (1)
Illinois
- NorthShore University HealthSystem - Evanston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 10 participants |
| Start Date | 2018-06-29 |
| Est. Completion | 2021-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT04043897
The ClinicalTrials.gov registry entry for NCT04043897 describes a study currently listed as recruiting, categorized as Phase 2. The registered enrollment target is 10 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Eugene F Yen, MD, which has 1 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Microscopic Colitis appearing as the primary indexed condition, and to 1 intervention - of which Rifaximin 550mg is the first listed.
NCT04043897 reports 1 study location spanning 1 distinct geographic area - top geographies include Illinois.
Frequently Asked Questions
What is clinical trial NCT04043897 about?
NCT04043897 is a clinical study titled "Efficacy and Safety of Oral Rifaximin in Patients With Active Microscopic Colitis". This is an open label study looking at rifaximin therapy for the treatment of microscopic (collagenous or lymphocytic) colitis.
What is the current status of trial NCT04043897?
This trial is currently recruiting. It is a Phase 2 study. The enrollment target is 10 participants. The study started on 2018-06-29. Estimated completion is 2021-12.
What conditions does trial NCT04043897 study?
This clinical trial studies the following conditions: Microscopic Colitis.
What interventions are being tested in trial NCT04043897?
The interventions under investigation include: Rifaximin 550mg (DRUG).
Who is sponsoring clinical trial NCT04043897?
This trial is sponsored by Eugene F Yen, MD, which has 1 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04043897 being conducted?
This trial has 1 study location across Illinois. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.